University Hospital of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.
Cantonal Hospital of Lucerne, Spitalstrasse, 6004, Lucerne, Switzerland.
Lung Cancer. 2021 Jun;156:136-139. doi: 10.1016/j.lungcan.2021.04.017. Epub 2021 Apr 24.
Ten years ago, RET-fusions were discovered as oncogenic drivers and potential drug targets in approximately 1% of metastatic lung adenocarcinomas. Several multikinase inhibitors were tested in clinical trials, however, their antitumor activity was limited. Recently, two selective and potent RET-inhibitors were approved for the treatment of patients with metastatic RET-fusion-positive lung cancer (RET-NSCLC). Here, we discuss the two RET-inhibitors selpercatinib and pralsetinib, and the management of patients with RET-fusion positive NSCLC.
十年前，RET 融合被发现是大约 1%的转移性肺腺癌中的致癌驱动因素和潜在的药物靶点。几种多激酶抑制剂已在临床试验中进行了测试，但它们的抗肿瘤活性有限。最近，两种选择性和有效的 RET 抑制剂被批准用于治疗转移性 RET 融合阳性肺癌（RET-NCLC）患者。在这里，我们讨论了两种 RET 抑制剂塞尔帕替尼和普拉替尼，以及 RET 融合阳性 NSCLC 患者的管理。
